InSilico Medicine (HKG:3696) said Tuesday that it has nominated its investigational drug ISM9546 as a candidate for detailed lab and animal testing to treat autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis.
The company said ISM9546, designed by its Pharma.AI platform, is its 35th preclinical candidate nomination since 2021, according to a Tuesday filing with the Hong Kong Exchange.
Shares were last down almost 7% in morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.